Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Lymphoma
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). 2) Bcl-2 protein overexpression by immunohistochemistry. 3) Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2. 4) Life expectancy of more than 6 months.
  

You may not be eligible for this study if the following are true:

• 1) Current diagnosis of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma (gray-zone lymphoma), primary mediastinal (thymic) large B-cell lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL. 2) Prior treatment for indolent lymphoma. 3) Contraindication to any of the individual components of polatuzumab vedotin and R-CHP, including prior receipt of anthracyclines, history of severe allergic or anaphylactic reactions to murine monoclonal antibodies, or known sensitivity or allergy to murine products. 4) Prior use of any monoclonal antibody within 3 months and any investigational therapy within 28 days prior to the start of Cycle 1.